Sartorius to acquire Albumedix for $502m

By Rachel Arthur

- Last updated on GMT

Pic:getty/andyroberts
Pic:getty/andyroberts

Related tags Sartorius Sartorius stedim biotech Cell therapies Viral vectors Vaccines Cell culture Cell culture media

Life science group Sartorius will acquire UK recombinant albumin-based solution company Albumedix.

Recombinant human albumin is a critical component in the manufacture of biopharmaceuticals, particularly in modalities such as cell therapies, viral therapies and vaccines.

Satorius will make the acquisition via its French subgroup Sartorius Stedim Biotech, acquiring 100% of Albumedix from private investors for £415m ($502m).

Cell culture media business

Founded in 1984, Nottingham-based Albumedix has more than 100 employees and is expected to generate revenue of approximately £33m ($40m) in 2022 with a significant double-digit EBITDA margin.

It provides recombinant albumin-based solutions: with recombinant human albumin being an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies.

Albumedix will become part of the Bioprocess Solutions Division, and its existing 72,000-square-foot site in Nottingham will be established as a center of excellence for innovation and GMP-compliant production of critical raw materials.

“Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials,”​ said René Fáber, member of the Executive Board for the Bioprocess Solutions Division of Sartorius.

“This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones.”

Jonas S. Møller, CEO of Albumedix, said Sartorius will help the company strengthen its market reach and broaden its innovation capacity, as well as significantly scaling up its existing platform.

“We are delighted to be joining forces with Sartorius and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers,”​ he said.

The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us

Products

View more

Webinars